MX2016012536A - Rnasa para su uso en el tratamiento o la prevencion de infecciones virales. - Google Patents

Rnasa para su uso en el tratamiento o la prevencion de infecciones virales.

Info

Publication number
MX2016012536A
MX2016012536A MX2016012536A MX2016012536A MX2016012536A MX 2016012536 A MX2016012536 A MX 2016012536A MX 2016012536 A MX2016012536 A MX 2016012536A MX 2016012536 A MX2016012536 A MX 2016012536A MX 2016012536 A MX2016012536 A MX 2016012536A
Authority
MX
Mexico
Prior art keywords
viral infections
onconase
treating
preventing viral
ribonucleases
Prior art date
Application number
MX2016012536A
Other languages
English (en)
Inventor
Hodge Thomas
Original Assignee
Tamir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tamir Biotechnology Inc filed Critical Tamir Biotechnology Inc
Publication of MX2016012536A publication Critical patent/MX2016012536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Las ribonucleasas de la súper familia RNasa A o un derivado funcional de las mismas son ampliamente útiles para el tratamiento o prevención de las infecciones virales causadas por los virus clasificados en los Grupos I, II, IV y V de Baltimore en sujetos mamíferos.
MX2016012536A 2014-03-28 2015-03-26 Rnasa para su uso en el tratamiento o la prevencion de infecciones virales. MX2016012536A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201414229816A 2014-03-28 2014-03-28
US201414247723A 2014-04-08 2014-04-08
US201414316893A 2014-06-27 2014-06-27
US201462040885P 2014-08-22 2014-08-22
US201462063551P 2014-10-14 2014-10-14
US201562102671P 2015-01-13 2015-01-13
US201514667282A 2015-03-24 2015-03-24
PCT/US2015/022670 WO2015148768A2 (en) 2014-03-28 2015-03-26 Rnase for use in treating or preventing viral infections

Publications (1)

Publication Number Publication Date
MX2016012536A true MX2016012536A (es) 2017-04-06

Family

ID=53284490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012536A MX2016012536A (es) 2014-03-28 2015-03-26 Rnasa para su uso en el tratamiento o la prevencion de infecciones virales.

Country Status (9)

Country Link
EP (1) EP3122372B1 (es)
JP (1) JP2017512837A (es)
AU (1) AU2015236040B2 (es)
BR (1) BR112016022214A2 (es)
CA (2) CA3061666C (es)
CL (1) CL2016002442A1 (es)
IL (1) IL247938A0 (es)
MX (1) MX2016012536A (es)
WO (1) WO2015148768A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
MX2017016368A (es) 2015-06-15 2018-04-24 Tamir Biotechnology Inc Farmaceuticos para tratamiento de infecciones virales de los ojos.
MX2018003528A (es) * 2015-09-25 2018-11-09 Okogen Inc Tratamiento de conjuntivitis viral utilizando ranpirnasa y/o anfinasa.
WO2017142807A1 (en) * 2016-02-16 2017-08-24 Tamir Biotechnology, Inc. Treatment or prevention of zika virus infections by administration of a ribonuclease
WO2021188854A1 (en) * 2020-03-20 2021-09-23 Orgenesis Inc. Ribonucleases for treating viral infections
MX2023002337A (es) * 2020-08-27 2023-05-12 Betahealth Llc Composición y métodos para el tratamiento o profilaxis de coronavirus y cánceres.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728805A (en) 1988-04-06 1998-03-17 Alfacell Corp. Pharmaceuticals and method for making them
US5559212A (en) 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US6239257B1 (en) 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
US7229824B2 (en) 2003-07-17 2007-06-12 Alfacell Corporation Ribonucleases and methods of making them recombinantly
US7544487B2 (en) * 2004-02-13 2009-06-09 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
EP3613761A1 (en) 2008-11-26 2020-02-26 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
US8518399B2 (en) 2010-11-17 2013-08-27 Tamir Biotechnology, Inc. Methods of treating infections originating from viruses in the herpesviridae family
US8663964B2 (en) 2011-07-20 2014-03-04 Tamir Biotechnology, Inc. Methods of treating human papillomavirus

Also Published As

Publication number Publication date
EP3122372A2 (en) 2017-02-01
CA3061666C (en) 2021-04-27
AU2015236040B2 (en) 2017-12-07
WO2015148768A2 (en) 2015-10-01
AU2015236040A1 (en) 2016-10-06
BR112016022214A2 (pt) 2017-10-24
EP3122372B1 (en) 2018-11-28
IL247938A0 (en) 2016-11-30
WO2015148768A3 (en) 2015-12-30
JP2017512837A (ja) 2017-05-25
CA2942706C (en) 2020-01-14
CA2942706A1 (en) 2015-10-01
CL2016002442A1 (es) 2017-05-19
CA3061666A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
MX2016012536A (es) Rnasa para su uso en el tratamiento o la prevencion de infecciones virales.
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MX2017005252A (es) Metodos para la preparacion de ribosidos.
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EP3119418A4 (en) Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
WO2015153889A3 (en) Materials and methods for the treatment of latent viral infection
EP3370754A4 (en) METHODS FOR INCREASING ERYTHROCYTE RATES AND TREATING INEFFECTIVE ERYTHROPOISIS
IL258846A (en) Nicotinamide for use in the treatment and prevention of optic neurodegenerative disorder
EP3474861A4 (en) COMPOUNDS COMPRISING HMOS FOR THE PREVENTION AND / OR TREATMENT OF VIRAL AND / OR BACTERIAL INFECTIONS.
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EP3432891A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE
EP3166615A4 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
EP3658679A4 (en) RAPID DETECTION AND ENUMERATION OF VIRUSES, BACTERIOPHAGES AND / OR BACTERIA
PH12017500602A1 (en) Methods for treating ocular conditions
MX2017016437A (es) Metodos de purificacion y/o inactivacion viral.
EP3217974A4 (en) Method for treating, preventing, or reducing the risk of skin infection
EP3353304A4 (en) TREATMENT OF VIRAL CONJUNCTIVITIS WITH RANPIRNASE AND / OR AMPHINASE
EP3195140A4 (en) Malicious message detection and processing
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
EP3261439A4 (en) METHOD AND MATERIALS FOR TREATING HUMAN IMMUNE WEAKAGE VIRUS INFECTIONS
EP3122190A4 (en) Compositions and related methods for treating and preventing viral and retroviral infections
EP3538888A4 (en) COMBINATION THERAPIES FOR TREATING BIPOLAR DISORDER AND METHOD FOR USE THEREOF